Characteristics of patients who received myeloablative conditioning regimens
| Variable . | Donor type . | P . | |
|---|---|---|---|
| Haplo PTCy/CNI/MMF . | MUD PTCy/CNI/MMF . | ||
| No. of patients | 825 | 97 | |
| Age, median (range), y | 45 (18-75) | 50 (18-71) | .002 |
| Age group | |||
| ≤55 y | 591 (72) | 55 (57) | |
| >55 y | 234 (28) | 42 (43) | |
| Race | .001 | ||
| White | 567 (69) | 85 (88) | |
| Other | 258 (31) | 12 (12) | |
| Sex | .52 | ||
| Male | 462 (56) | 51 (53) | |
| Female | 363 (44) | 46 (47) | |
| Performance score | .60 | ||
| 90-100 | 461 (56) | 57 (59) | |
| ≤80 | 348 (42) | 37 (38) | |
| Not reported | 16 (2) | 3 (3) | |
| Comorbidity score | .56 | ||
| ≤2 | 451 (55) | 50 (52) | |
| ≥3 | 374 (45) | 47 (48) | |
| Recipient CMV serostatus | .04 | ||
| Negative | 245 (30) | 41 (42) | |
| Positive | 577 (70) | 56 (58) | |
| Not reported | 3 (< 1) | __ | |
| Disease | .01 | ||
| Acute myeloid leukemia | 453 (55) | 47 (48) | |
| Acute lymphoblastic leukemia | 268 (32) | 27 (28) | |
| Myelodysplastic syndrome | 104 (13) | 23 (24) | |
| Disease risk index | .39 | ||
| Low/intermediate risk | 627 (76) | 77 (79) | |
| High/very high risk | 168 (20) | 19 (20) | |
| Not reported | 30 (4) | 1 (1) | |
| Interval from diagnosis to HCT, median (IQR), mo | |||
| Low/intermediate risk | 6 (4-9) | 6 (5-10) | .75 |
| High/very high risk | 12 (5-29) | 8 (5-14) | .08 |
| Conditioning regimen | .003 | ||
| TBI | 414 (50) | 33 (34) | |
| TBI/fludarabine | 360 | 15 | |
| TBI/cyclophosphamide | 39 | 4 | |
| TBI/other agents | 15 | 14 | |
| Non-TBI | 411 (50) | 64 (66) | |
| Busulfan/cyclophosphamide | 213 | 20 | |
| Fludarabine/busulfan | 153 | 43 | |
| Fludarabine/melphalan/thiotepa | 45 | 1 | |
| Graft type | .003 | ||
| Bone marrow | 216 (26) | 12 (12) | |
| Peripheral blood | 609 (74) | 85 (88) | |
| Transplant period | .006 | ||
| 2011-2014 | 151 (19) | 7 (7) | |
| 2015-2018 | 674 (81) | 90 (93) | |
| Variable . | Donor type . | P . | |
|---|---|---|---|
| Haplo PTCy/CNI/MMF . | MUD PTCy/CNI/MMF . | ||
| No. of patients | 825 | 97 | |
| Age, median (range), y | 45 (18-75) | 50 (18-71) | .002 |
| Age group | |||
| ≤55 y | 591 (72) | 55 (57) | |
| >55 y | 234 (28) | 42 (43) | |
| Race | .001 | ||
| White | 567 (69) | 85 (88) | |
| Other | 258 (31) | 12 (12) | |
| Sex | .52 | ||
| Male | 462 (56) | 51 (53) | |
| Female | 363 (44) | 46 (47) | |
| Performance score | .60 | ||
| 90-100 | 461 (56) | 57 (59) | |
| ≤80 | 348 (42) | 37 (38) | |
| Not reported | 16 (2) | 3 (3) | |
| Comorbidity score | .56 | ||
| ≤2 | 451 (55) | 50 (52) | |
| ≥3 | 374 (45) | 47 (48) | |
| Recipient CMV serostatus | .04 | ||
| Negative | 245 (30) | 41 (42) | |
| Positive | 577 (70) | 56 (58) | |
| Not reported | 3 (< 1) | __ | |
| Disease | .01 | ||
| Acute myeloid leukemia | 453 (55) | 47 (48) | |
| Acute lymphoblastic leukemia | 268 (32) | 27 (28) | |
| Myelodysplastic syndrome | 104 (13) | 23 (24) | |
| Disease risk index | .39 | ||
| Low/intermediate risk | 627 (76) | 77 (79) | |
| High/very high risk | 168 (20) | 19 (20) | |
| Not reported | 30 (4) | 1 (1) | |
| Interval from diagnosis to HCT, median (IQR), mo | |||
| Low/intermediate risk | 6 (4-9) | 6 (5-10) | .75 |
| High/very high risk | 12 (5-29) | 8 (5-14) | .08 |
| Conditioning regimen | .003 | ||
| TBI | 414 (50) | 33 (34) | |
| TBI/fludarabine | 360 | 15 | |
| TBI/cyclophosphamide | 39 | 4 | |
| TBI/other agents | 15 | 14 | |
| Non-TBI | 411 (50) | 64 (66) | |
| Busulfan/cyclophosphamide | 213 | 20 | |
| Fludarabine/busulfan | 153 | 43 | |
| Fludarabine/melphalan/thiotepa | 45 | 1 | |
| Graft type | .003 | ||
| Bone marrow | 216 (26) | 12 (12) | |
| Peripheral blood | 609 (74) | 85 (88) | |
| Transplant period | .006 | ||
| 2011-2014 | 151 (19) | 7 (7) | |
| 2015-2018 | 674 (81) | 90 (93) | |
Data are no, of patients (percentage of study group), unless otherwise stated.
IQR, interquartile range.